EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Optimizing treatment for metastatic castration‐resistant prostate cancer: Food and Drug Administration‐approved therapies, emerging strategies, and biomarker‐driven approaches

Faisal Saeed iD, Jacob E Berchuck, Mehmet Asim Bilen iD, Jatin S Gandhi, Bassel Nazha iD, Jacqueline T Brown, David M Schuster, Ashesh B Jani, Jindan Yu, Lara R Harik

Cancer · 2025

DOI: 10.1002/cncr.70037 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, 2025. Verfasst von Faisal Saeed und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Biomarkers, Tumor. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 113 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic castration‐resistant prostate cancer (mCRPC) remains a lethal stage of disease progression despite substantial therapeutic advancements. Driven largely by androgen receptor (AR) signaling, prostate cancer eventually develops resistance to AR‐directed therapies, necessitating alternative strategies. In recent years, several novel agents have received US Food and Drug Administration approval for mCRPC, including next‐generation AR‐signaling inhibitors, poly(adenosine diphosphate‐ribose) polymerase inhibitors, targeted radioligand therapy, and immunotherapy. Although these treatments have extended survival, resistance mechanisms and optimal sequencing remain key challenges. Molecular profiling has uncovered distinct genomic alterations—such as defects in homologous recombination repair genes and mismatch repair alterations—that guide therapeutic decision making. In parallel, novel treatment modalities are being explored, including AR degraders, antibody–drug conjugates, T‐cell engagers, and epigenetic modulators. This review critically evaluates current US Food and Drug Administration‐approved therapies for mCRPC, examines emerging therapeutic strategies under clinical development, and discusses evolving biomarker‐driven approaches that aim to personalize treatment and improve outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantBiomarkers, TumorHumansMaleUnited States Food and Drug AdministrationUnited StatesDrug ApprovalReceptors, AndrogenImmunotherapyPoly(ADP-ribose) Polymerase InhibitorsMolecular Targeted TherapyDrug Resistance, NeoplasmNeoplasm MetastasisAndrogen Receptor Antagonists

Stichwörter der Autor:innen

androgen receptor‐signaling inhibitors (ARSIs)metastatic castration‐resistant prostate cancer (mCRPC)poly(adenosine diphosphate‐ribose) polymerase (PARP) inhibitorsprecision oncologyprostate cancerradioligand therapytargeted therapy

Substanzen

Biomarkers, TumorReceptors, AndrogenPoly(ADP-ribose) Polymerase InhibitorsAndrogen Receptor Antagonists

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
  • Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA.

ORCID-Profile: Faisal Saeed, Mehmet Asim Bilen, Bassel Nazha

Zitieren

APA

Saeed, F., Berchuck, J. E., Bilen, M. A., Gandhi, J. S., Nazha, B., Brown, J. T., Schuster, D. M., Jani, A. B., Yu, J., & Harik, L. R. (2025). Optimizing treatment for metastatic castration‐resistant prostate cancer: Food and Drug Administration‐approved therapies, emerging strategies, and biomarker‐driven approaches. Cancer. https://doi.org/10.1002/cncr.70037

Vancouver

Saeed F, Berchuck JE, Bilen MA, Gandhi JS, Nazha B, Brown JT, et al. Optimizing treatment for metastatic castration‐resistant prostate cancer: Food and Drug Administration‐approved therapies, emerging strategies, and biomarker‐driven approaches. Cancer. 2025. doi:10.1002/cncr.70037

BibTeX
@article{Saeed2025,
  author = {Saeed, Faisal and Berchuck, Jacob E and Bilen, Mehmet Asim and Gandhi, Jatin S and Nazha, Bassel and Brown, Jacqueline T and Schuster, David M and Jani, Ashesh B and Yu, Jindan and Harik, Lara R},
  title = {Optimizing treatment for metastatic castration‐resistant prostate cancer: Food and Drug Administration‐approved therapies, emerging strategies, and biomarker‐driven approaches},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.70037}
}
Kostenlos starten →